Clinical Trial Update: Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment [Phase 4]

View source ↗

Summary

A Phase 4 trial updating efficacy and safety of one-year alglucosidase alfa treatment in Chinese patients with infantile-onset Pompe disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glycogen Storage Disease Type Ii

Drugs mentioned

• Alglucosidase alfa (alglucosidase alfa)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Glycogen Storage Disease Type II | Phase 4 | Status: COMPLETED